Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAXAIR vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Prevention and treatment of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, COPD)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via glucuronidation and sulfate conjugation; also metabolized by catechol-O-methyltransferase (COMT).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
55–70%, primarily to albumin.
65% bound to albumin
2.0–2.5 L/kg; indicates extensive distribution into tissues.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Inhalation: approximately 20–30% of the delivered dose reaches the systemic circulation; oral bioavailability is <1% due to first-pass metabolism.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No specific dose adjustment required; medication is primarily hepatically metabolized.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No specific dose adjustment guidelines; use caution in severe hepatic impairment due to potential decreased drug clearance.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Children 6-11 years: 1-2 inhalations (170-340 mcg) via oral inhalation every 4-6 hours as needed; maximum 8 inhalations per day. Children ≥12 years: same as adult.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
No specific dose adjustment; monitor for increased sensitivity to beta-agonists (e.g., tachycardia, tremor) and concurrent diseases (e.g., cardiovascular disorders).
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA boxed warning.
No FDA black box warning.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmias, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to pirbuterol or any component,Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
No specific food interactions. Avoid excessive caffeine intake as it may increase stimulant effects. Grapes, grapefruit, and grapefruit juice have no significant interaction with pirbuterol.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/day in rats and up to 10 mg/kg/day in rabbits, but fetal growth retardation and increased mortality were observed at maternally toxic doses. Risk to human fetus cannot be ruled out. Use during pregnancy only if potential benefit justifies potential risk.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Unknown if pirbuterol is excreted in human milk. Due to lack of data and potential for serious adverse reactions in nursing infants, caution is advised. M/P ratio not determined.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No specific pharmacokinetic data in pregnancy; standard dosing recommended. Beta-agonists may delay preterm labor; use with caution.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
MAXAIR (pirbuterol) is a beta-2 adrenergic agonist for asthma and COPD. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, or hypertension. Monitor for paradoxical bronchospasm; if occurs, discontinue immediately. Not indicated for acute severe asthma exacerbations unless patient is closely monitored. Can cause hypokalemia, especially with concomitant use of corticosteroids or diuretics. Administer with a spacer device to improve lung deposition and reduce oral side effects.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Use only as prescribed; do not exceed recommended doses.,Rinse mouth after inhalation to prevent oral thrush.,Contact doctor if symptoms worsen or if you need more than usual doses.,Do not share the inhaler; keep it clean.,Seek immediate medical help if you experience chest pain, rapid heartbeat, or severe wheezing after use.,Inform your doctor if you have heart disease, high blood pressure, seizures, or diabetes.,Avoid using with other asthma medications without consulting your doctor.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAXAIR vs AEROLATE, answered by our medical review team.
MAXAIR is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular c AMP.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAXAIR and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAXAIR is: 2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAXAIR and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAXAIR is classified as Category C. FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, maxair (pirbuterol) showed no teratogenic effects at doses up to 20 mg/kg/da. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.